{"id":"NCT00577993","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients","officialTitle":"Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) for Stage IV Indolent Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"1998-03-16","primaryCompletion":"2017-08-24","completion":"2017-08-24","firstPosted":"2007-12-20","resultsPosted":"2020-11-16","lastUpdate":"2020-11-16"},"enrollment":210,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"Fludarabine","otherNames":["2-fluoro-Ara Amp"]},{"type":"DRUG","name":"Novantrone","otherNames":["Mitoxantrone"]},{"type":"DRUG","name":"Decadron","otherNames":["Dexamethasone"]},{"type":"DRUG","name":"Rituximab","otherNames":["Chimeric Anti-CD20 Antibody","Anti-CD20","IDEC-C2B8"]},{"type":"DRUG","name":"Interferon","otherNames":["Interferon Alpha-2b","IFN"]},{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Vincristine","otherNames":[]},{"type":"DRUG","name":"Bleomycin","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Etoposide","otherNames":[]},{"type":"DRUG","name":"Cisplatin","otherNames":[]},{"type":"DRUG","name":"Ara-C","otherNames":[]},{"type":"DRUG","name":"Methyl-Prednisolone","otherNames":[]},{"type":"DRUG","name":"Procarbazine","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]}],"arms":[{"label":"1: FND + Rituximab Followed by Interferon","type":"ACTIVE_COMPARATOR"},{"label":"2: FND Followed by Interferon & Rituximab","type":"ACTIVE_COMPARATOR"},{"label":"3: CHOD-Bleo, ESHAP, NOPP + Rituximab Followed by Interferon","type":"ACTIVE_COMPARATOR"}],"summary":"The goal of this clinical research study is to compare chemotherapy given with rituximab to chemotherapy followed by rituximab. The safety of both treatment schedules will be studied. Laboratory tests of genetic changes in blood and bone marrow before and during the study will also be monitored.","primaryOutcome":{"measure":"Number of Participants With Overall Survival (10 Years) by Treatment","timeFrame":"10 Years","effectByArm":[{"arm":"Fludarabine,Mitoxantrone, and Dexamethasone (FND)-Rituximab","deltaMin":59,"sd":null},{"arm":"Rituximab- Fludarabine,Mitoxantrone, and Dexamethasone (FND)","deltaMin":58,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":67,"n":78},"commonTop":["Fatigue","Neutropenia","Alopecia","Abdominal Pain","Infection"]}}